IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
06 mai 2024 11h00 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
06 mai 2024 08h00 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
01 mai 2024 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with...
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
29 avr. 2024 08h45 HE
|
GRI Bio, Inc.
LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
17 avr. 2024 16h05 HE
|
Serina Therapeutics, Inc.
- Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development - HUNTSVILLE, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (NYSE...
IMUNON Reports Compliance with Nasdaq Listing Requirements
11 avr. 2024 08h00 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
13 mars 2024 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
IMUNON Announces Leadership Change
12 mars 2024 17h00 HE
|
Imunon, Inc.
Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged. LAWRENCEVILLE, N.J., March 12, 2024 ...
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
27 févr. 2024 08h30 HE
|
Imunon, Inc.
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
22 févr. 2024 08h00 HE
|
Imunon, Inc.
Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...